- cafead   Aug 29, 2024 at 11:12: AM
via
article source
- Artiva has two-bagger potential in the eyes of multiple Wall Street analysts.
- Its cell therapies could provide a much more efficient treatment of autoimmune diseases.
- Artiva faces years of hurdles, but investors could make out handsomely if it is successful.
article source